GlassScriptPhysician profile
Adelynn V Gerstenberger
NPI 1861642910
$1,674.79
in general payments reported to CMS, 2019-2025
30 companies · $752 in 2025
The $752 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $450 · 2024: $473 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,580 · Education: $95.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,579.79 |
| Education | $95.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $220.76 | 2023-2025 | Reblozyl, Opdivo |
| Astrazeneca Pharmaceuticals LP | $128.40 | 2023-2025 | Tagrisso, Enhertu, Lynparza |
| Genzyme Corporation | $124.97 | 2025 | |
| Karyopharm Therapeutics INC. | $113.86 | 2023 | Xpovio |
| Incyte Corporation | $108.77 | 2024 | Monjuvi |
| Merck Sharp & Dohme LLC | $107.33 | 2024-2025 | Keytruda, Lynparza |
| Daiichi Sankyo INC. | $96.36 | 2024-2025 | Enhertu, Injectafer |
| Janssen Biotech, INC. | $94.12 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Novartis Pharmaceuticals Corporation | $81.07 | 2024-2025 | |
| Deciphera Pharmaceuticals INC. | $52.43 | 2023-2025 | Qinlock, Romvimza |
| Beone Medicines USA, INC. | $48.18 | 2025 | Brukinsa |
| Taiho Oncology, INC. | $40.32 | 2023-2024 | |
| Genentech USA, INC. | $36.22 | 2023-2024 | Venclexta, Gazyva |
| Genmab U.S., INC. | $35.97 | 2025 | Tivdak |
| Pfizer INC. | $35.03 | 2023-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $34.24 | 2024-2025 | Jemperli, Ojjaara, Zejula |
| Bayer Healthcare Pharmaceuticals INC. | $33.35 | 2023-2025 | |
| Gilead Sciences, INC. | $29.87 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $28.22 | 2024 | Libtayo |
| Monteris Medical Corporation | $26.55 | 2023 | Neuroblate |
| Celgene Corporation | $25.60 | 2023 | Reblozyl |
| Alexion Pharmaceuticals, INC. | $24.53 | 2023 | Ultomiris |
| Fennec Pharmaceuticals, INC. | $23.64 | 2025 | Fyarro |
| Geron Corporation | $21.52 | 2025 | Rytelo |
| Pharmacosmos Therapeutics INC. | $19.99 | 2024 | Monoferric |
| Sobi, INC | $18.44 | 2024 | |
| Cti Biopharma Corp. | $18.32 | 2023 | Vonjo |
| Eisai INC. | $17.47 | 2025 | |
| Seagen INC. | $15.39 | 2023 | Adcetris |
| Abbvie INC. | $13.87 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adelynn Gerstenberger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.